Publication Topic

Hackshaw A, Cohen SS, Reichert H, Kansal AR, Chung KC, Ofman JJ. 2021. Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK. Brit J Cancer, open access.

Gillezeau C, Movva N, Fryzek J, Rabon-Stith K, Brohawn PZ, Gerwen M van, Taioli E. Molecular epidemiology study of interferon gamma (IFN-γ) expression in urothelial bladder cancer (UBC). Poster presentation [preview] at 37^th ICPE (International Conference on Pharmacoepidemiology & Therapeutic Rick Management), virtual conference, August 2021.

Christiansen CF, Farkas DK, Fryzek JP, Romagnani P, Nørgaard M, Rothman KJ, Toft Sørensen H. Risk and prognosis of cancer after acute kidney injury. Presentation to the 36^th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Berlin, Germany, August 2020.

Dronin-Fenton D, Dalvi T, Movva N, Pedersen I, Hansen H, Fryzek J, Mellemgaard A, Rasmussen T, Klein A, Hamilton-Dutoit S, Nørgaard M. PD-L1 expression and survival in stage III unresectable non-small cell lung cancer patients in Denmark. Accepted for presentation to a virtual meeting (due to COVID-19) of the European Society for Medical Oncology (ESMO), abstract #2865, August 2020.

Bylsma LC, Dean RGK, Lowe K, Sangaré L, Alexander D, Fryzek J. 2019. The incidence of infusion reactions associated with monoclonal antibody drugs targeting the epidermal growth factor receptor in metastatic colorectal cancer patients: A systematic literature review and meta-analysis of patient and study characteristics. Cancer Med Aug 3, doi: 10.1002/cam4.2413 [Epub ahead of print].

Cronin-Fenton D, Dalvi T, Fryzek J, Hansen H, Hamilton-Dutoit S, Hedgeman E, Mellemgaard A, Norgaard M, Pedersen L, Potter D, Rasmussen TR, Rigas J, Shire N, Sorensen HT, Walker J. PD-L1 expression, EGFR and KRAS mustations in stage III unresectables non-small cell lung cancer (NSCLC) patients. Presented at the International Society for Pharmacoepidemiology Annual Conference, August 22-26, 2018, Prague, Czech Republic.

Cronin-Fenton D, Dalvi T, Hedgeman E, Norgaard M, Pedersen L, Hansen H, Fryzek J, Walker J, Mellemgaard A, Rasmussen TR, Shire N, Rigas J, Potter D, Hamilton-Dutoit S, Sorensen HT. PD-L1 expression, EGFR and KRAS mustations in stage III unresectables non-small cell lung cancer (NSCLC) patients. Presented at the American Association for Cancer Research (AACR) Annual Meeting 2018, April 14-18, 2018, Chicago, IL.

Beebe-Dimmer JL, Ruterbusch JJ, Bylsma LC, Gillezeau C, Fryzek J, Schultz NM, Flanders SC, Barlev A, Heath E, Quek RGW. 2018. Patterns of bicalutamide use in prostate cancer treatment: A U.S. real-world analysis using the SEER-Medicare database. Adv Ther 35(1):1438-1451.

Schwartz KL, Simon MS, Bylsma LC, Ruterbusch JJ, Beebe-Dimmer JL, Schultz NM,  Flanders SC, Barlev A, Fryzek JP, Quek RGW. 2018. Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States. Cancer 124(10):2104-2114.

Bylsma LC, Gillezeau C, Garawin T, Kelsh M, Fryzek J, Sangare L, Lowe KA. Prevalence of RAS and BRAF Mutations in Metastatic Colorectal Cancer (mCRC) Patients by Tumor Location. Presented at the Gastrointestinal Cancers Symposium, January 18-20, 2018, San Francisco, CA.

Fryzek JP, Reichert H, Summers N, Townes L, Deuson R, Alexander DD, Vanderpuye-Orgle J. 2018. Indirect treatment comparison of cabazitaxel for patients with metastatic castrate-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen. PLoS One 13(4):e0195790.

Suh M, Wikoff D, Harvey S, Mittal L, Lipworth L, Goodman M, Goodmanson A, Ring C, Rohr A, Proctor D. Hexavalent chromium and stomach cancer: A systematic review and meta-analysis. Presented at Joint Annual Meeting of International Society of Exposure Science and International Society for Environmental Epidemiology (ISES-ISEE 2018), Ottawa, Canada, August 2018.

Mullins M, Jiang X, Bylsma LC, Fryzek JP, Reichert H, Chen EC, Kummar S, Rosenthal A. 2017. Cold agglutinin disease burden: A longitudinal analysis of anemia, medications, transfusions, and healthcare utilization. Blood Adv 1:839-848.

Cronin-Fenton D, Dalvi T, Hedgeman E, Norgaard M, Pedersen L, Hansen H, Fryzek J, Lawrence D, Walker J, Mellemgaard A, Rasmussen TR, Shire N, Rigas J, Potter D, Hamilton-Dutoit S, Sorensen HT. PD-L1 expression, EGFR and KRAS mutations in First-Line Therapy (1L) for non-small cell lung cancer (NSCLC) patients. Presented at the 18th World Conference on Lung Cancer of the International Association for the Study of Lung Cancer (IASLC) 2017, October 15-18, 2017, Yokohama, Japan.

Suh M, Harvey S, Wikoff D, Mittal L, Ring C, Goodmanson A, Proctor D. Meta-analysis of hexavalent chromium and stomach cancer. Poster presented at Society of Toxicology Annual Meeting, Baltimore, MD, March 13, 2017.

Soff GA, Ray-Coquard I, Marfil Rivera LJ, Fryzek J, Mullins M, Bylsma LC, Park JK. Literature Review of Thrombopoietin Receptor Agonists (TPO-RA) for Chemotherapy-Induced Thrombocytopenia (CIT). Presented at the European Society for Medical Oncology 2017 Congress, September 8-12, 2017, Madrid, Spain.

Ruterbusch JJ, Bylsma LC, Fryzek J, Barlev A, et al. Bicalutamide Treatment Patterns in Elderly Prostate Cancer Patients: A Historical Cohort Study Using the Surveillance, Epidemiology and End Results Program (SEER)-Medicare Database. Presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual International Meeting, May 20-24, 2017, Boston, MA.

Fryzek JP, Ruterbusch JJ, Garabrant DH, Dalvi T, Beebe-Dimmer JL. Healthcare Resource Utilization and Costs of Care for Mesothelioma Medicare Beneficiaries. Presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual International Meeting, May 20-24, 2017, Boston, MA.

Garabrant DH, Alexander DD, Miller PE, Fryzek JP, Boffetta P, Teta MJ, Hessel PA, Craven VA, Kelsh MA, Goodman M. 2016. Response to Kay Teschke. Re: Mesothelioma among motor vehicle mechanics: An updated review and meta-analysis. Ann Occup Hyg 60(8):1036-1037.

Beebe-Dimmer JL, Fryzek JP, Yee CL, Dalvi T, Garabrant DH, Schwartz AG, Gadgeel S. 2016. Mesothelioma in the United States: A Surveillance, Epidemiology and End Results (SEER)-Medicare investigation of treatment patterns and overall survival. Clin Epidemiol 8:743-750.

Cronin-Fenton D , Dalvi T, Hedgeman E, Norgaard M, Pedersen L, Mortensen K, Midta A, Shire N, Brody R, Fryzek J, Lawrence D, Rigas J, Potter D, Walker J, Mellemgaard A, Rasmussen TR, Hamilton-Dutoit S, Sorensen HT. An interim assessment of key biomarkers (programmed cell death receptor ligand 1 (PD-L1) expression and epidermal growth factor receptor (EGFR) in third-line therapy non-small cell lung cancer (NSCLC) patients: A Danish cohort study. Presented at the 41st European Society for Medical Oncology (ESMO) Congress, October 7-11 2016, Copenhagen, Denmark.

Fryzek J, Alexander DD, Summers N, Fraysse J, Reichert H, Townes L, Vanderpuye-Orgle J. 2016. Indirect treatment comparison of cabazitaxel for patients with metastatic castration-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen. Value in Health 3:A139-A140.

Fryzek J, Alexander DD, Summers N, Fraysse J, Reichert H, Townes L, Vanderpuye-Orgle J. Indirect treatment comparison of cabazitaxel for patients with metastatic castration-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen. Presented at the 21st Annual International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 21-25, 2016, Washington, DC.

Suh M, Crump K, Mittal L, Hirsch S, Valdes Salgado R, BartlettC, Van Landingham C, Rohr A, Proctor DM. Inhalation cancer risk assessment of hexavalent chromium based on updated mortality for Painesville chromate production workers. Presented at the Society of Toxicology’s 55th Annual Meeting, New Orleans, LA, March 13-17, 2016.

Garabrant DH, Alexander DD, Miller PE, Fryzek JP, Boffetta P, Teta MJ, Hessel PA, Craven VA, Kelsh MA, Goodman M. 2016. Mesothelioma among motor vehicle mechanics: An updated review and meta-analysis. Ann Occup Hyg 60(1):8-26.

Bylsma LC, Alexander DD. A Review and Meta-analysis of Prospective Studies of Red and Processed Meat, Meat Cooking Methods, Heme Iron, Heterocyclic Amines and Prostate Cancer. Presented at the Experimental Biology Conference, April 2-6, 2016, San Diego, CA.

Bylsma LC, Alexander DD.2015. A review and meta-analysis of prospective studies of red and processed meat, meat cooking methods, heme iron, heterocyclic amines and prostate cancer. Nutr J 14(1):125.

Liu B, Kerath SM, Sekeres MA, Fryzek JP, Sreekantaiah C, Mason CR, Kolitz J, Taioli E. 2015. Myelodysplastic syndromes spatial clusters in disease etiology and outcome. Leuk Lymphoma 5:1-8.

Nguyen-Nielsen M, Wang L, Pedersen L, Braae Olesen A, Hou K, Mackey H, McCusker M, Basset-Seguin N, Fryzek JP, Vyberg M. 2015. The incidence of metastatic basal cell carcinoma in Denmark 1997-2010. Eur J Dermatol 25(5):463-8

Proctor D, Suh M, Thompson C, Hixon, G. Inhalation cancer risk assessment of titanium dioxide. Presented at the Society of Toxicology’s 54th Annual Meeting, San Diego, CA, March 22-26 2015.

Suh M, Mittal L, Hirsch S, Valdes R, Bartlett C, Rohr A, Proctor D. Lung cancer risk in chromate production workers exposed to hexavalent chromium. Presented at the Society of Toxicology’s 54th Annual Meeting, San Diego, CA, March 22-26, 2015 .

Proctor DM, Suh M, Mittal L, Hirsch S, Salgado RV, Bartlett C, Van Landingham C, Rohr A, Crump K. 2015. Inhalation cancer risk assessment of hexavalent chromium based on updated mortality for Painesville chromate production workers. J Expo Sci Environ Epidemiol 26(2):224-231. doi: 10.1038/jes.2015.77.

Liu B, Karath SM, Sekeres MA, Fryzek JP, Mutetwa BT, Sreekantaiah C, Mason C, Kolitz, Taioli E. Insights into the spatial clustering and disease etiology of myelodysplastic syndromes. Presented at the New York City Epidemiology Forum, February 27, 2015, New York City, NY.

Kerath SM, Sekeres MA, Fryzek JP, Mutetwa BT, Sreekantaiah C, Mason CR, Kolitz J, Taioli E. Clinical characteristics and outcomes in a large sample of MDS patients. Presented at the American Public Health Association (APHA) Annual Meeting and Exposition, November 15-19 2014, New Orleans, LA.

Cohen SS, Sadoff MM, Jiang X, Fryzek JP, Garabrant DH. A review and meta-analysis of cancer risks in relation to Portland cement exposure. Occup Environ Med. 2014 Nov;71(11):796-802.

Cohen SS, Skovbo S, Vestergaard H, Kristensen T, Moller M, Bindslev-Jensen C, Fryzek JP, Broesby-Olsen S.  2014. Epidemiology of systemic mastocytosis in Denmark. Br J Haematol 166(4):521-528.

Mehta J, Wang H, Fryzek JP, Iqbal SU, Mesa R. 2014. Health resource utilization and cost associated with myeloproliferative neoplasms (MPN) in a large United States health plan. Leuk Lymphoma 55(10), DOI: 10.3109/10428194.2013.879127.

Fryzek J, Garabrant DH, Pastula S,Jiang X. 2013. Response to Goldstein et al. J Occup Environ Med 55(11):1378.

Fryzek J, Pastula S, Jiang X, Garabrant DH. 2013. Childhood cancer incidence in Pennsylvania counties in relation to living in counties with hydraulic fracturing sites. J Occup Environ Med 55(7):796-801.

Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA. 2013. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol 92(4):289-297, https://doi.org/10.1111/ejh.12256.

Metha J, Le-Ruet O, Fryzek J, Iqbal U, Olivares R, Mesa R. Epidemiology of primary myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Presented at the European Cancer Congress (ESMO), September 27-October 1, 2013, Amsterdam, Netherlands.

Svendsen ML, Gammelager H, Sværke C, Yong M, Chia VM, Christiansen CF, Fryzek JP. 2013. Hospital visits among women with skeletal-related events secondary to breast cancer and bone metastases: A nationwide population-based cohort study in Denmark. Clin Epidemiol 5:97-103, DOI: 10.2147/CLEP.S42325.

Li J, Dalvi T, Pawaskar M, Tsai K, Caspard H, Fryzek J. Recent trends in the characteristics of patients with distant stage breast cancer in the United States Surveillance, Epidemiology and End Stage Disease program. Presented at the 2012 CTRC−AACR San Antonio Breast Cancer Symposium, December 4-8, 2012, San Antonio, TX.

Nielsen Nguyen M, Pedersen, Olesen Braae A, Wang L, Hou J, Mackey H, McCusker M, Basset-Seguin N, Fryzek J. The incidence of metastatic basal cell carcinoma in Denmark, 1997-2010. Presented at the 6th World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers in conjunction with the 8th EADO Congress, November 14-17 2012, Barcelona, Spain.

Youk AO, Buchanich JM, Fryzek J, Cunningham M, Marsh GM. 2012. An ecological study of cancer mortality rates in high altitude counties of the United States. High Alt Med Biol 13(2):98-104.

Boffetta P, Fryzek JP, Mandel JS. 2012. Occupational exposure to beryllium and cancer risk: A review of the epidemiologic evidence. Crit Rev Toxicol 42(2):107-118.

Kuehn C, Watson H, Ong K, Mohamed M, Ochoa JA, Fryzek J. Descriptive Epidemiology of Medical Device Use among Patients with Breast, Lung or Prostate Cancer in the National Inpatient Sample. Presented at the 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, August 23-26, 2012, Barcelona, Spain.

Alexander D, Weed D, Mink P, Mitchell M. 2012. A weight-of-evidence review of colorectal cancer in pesticide applicators: The agricultural health study and other epidemiologic studies. Int Arch Occup Environ Health 85(7):715–745.

Fordyce T, Mowat F, Fryzek J, Lau E. Incidence of metastatic hormone receptor positive (HR+) breast cancer in the United Kingdom: Data Needed. Presented at the 17th Annual International Society for Pharacoeconomics and Outcomes Research, June 2-6, 2012, Washington, DC.

Mitchell M, Taylor A, Lowe K, Langeberg W, et al. Prevalence of bone metastasis in breast cancer patients and subsequent survival: A systematic and quantitative review of the literature. Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, December 2011

Yong M, Christiansen CF, Gammelager H, Sværke C, Chia V, Atchison C, Fryzek J. Healthcare resource utilization among breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1997 – 2009). Presented at the 34th Annual San Antonio Breast Cancer Symposium, December 6-10, 2011, San Antonio, TX.

Yong M, Jensen AÖ, Jacobsen JB, Nørgaard M, Fryzek JP, Sørensen HT. 2011. Survival in breast cancer patients with bone metastases and skeletal-related events: A population-based cohort study in Denmark (1999-2007). Breast Cancer Res Treat 129(2):495-503.

Mitchell M, Taylor A, Lowe K, Langeberg W, et al. Prevalence of bone metastases among breast, lung, and prostate cancer patients. Presented at the 27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Chicago, IL, August 2011.

Yong M, Riis AH, Fryzek JP, Møller BK, Johnsen SP. 2011. Predictors and patterns of red blood cell transfusion use among newly diagnosed cancer patients with chemotherapy-associated anemia in Western Denmark (1998-2003). Clin Epidemiol 3:91-99.

Mitchell J, Mehta J, Lau E, Fryzek J. National-level descriptive epidemiology of pediatric acute lymphoblastic leukemia. Presented at the 24th Annual Meeting of the American Society of Pediatric Hematology/Oncology, April 13-16, 2011, Baltimore, MD.

Beebe-Dimmer J, Morgenstern H, Cetin K, Yee C, Bartoces M, Shahinian V, Fryzek J, Acquavella J, Schwartz KL. 2011. Androgen deprivation therapy and cataract incidence among elderly prostate cancer patients in the United States. Ann Epidemiol 21(3):156-163.

Jensen AØ, Jacobsen JB, Nørgaard M, Yong M, Fryzek JP, Sørensen HT. 2011. Incidence of bone metastases and skeletal-related events in breast cancer patients: A population-based cohort study in Denmark. BMC Cancer 11:29.

De Roos AJ, Deeg HJ, Onstad L, Kopecky KJ, Bowles EJ, Yong M, Fryzek J, Davis S. 2010. Incidence of myelodysplastic syndromes within a nonprofit healthcare system in western Washington state, 2005-2006. Am J Hematol 85(10):765-770.

Cronin-Fenton DP, Søndergaard F, Pedersen LA, Fryzek JP, Cetin K, Acquavella J, Baron JA, Sørensen HT. 2010. Hospitalisation for venous thromboembolism in cancer patients and the general population: A population-based cohort study in Denmark, 1997-2006. Br J Cancer 103(7):947-953.

Nørgaard M, Jensen AØ, Jacobsen JB, Cetin K, Fryzek JP, Sørensen HT. 2010. Skeletal related events, bone metastasis and survival of prostate cancer: A population based cohort study in Denmark (1999 to 2007). J Urol 184(1):162-167.

Gatto NM, Kelsh MA, Mai DH, Suh M, Proctor DM. 2010. Occupational exposure to hexavalent chromium and cancers of the gastrointestinal tract: A meta-analysis. Cancer Epidemiol 34(4):388-99.

Cetin K, Beebe-Dimmer JL, Fryzek JP, Markus R, Carducci MA. 2010. Recent time trends in the epidemiology of stage IV prostate cancer in the United States: Analysis of data from the Surveillance, Epidemiology, and End Results Program. Urology 75(6):1396-1404.

Youk AO, Buchanich JM, Marsh GM, Fryzek JP. An Ecological Study of Cancer Mortality Rates in High Altitude Counties of the United States. Presented at the Society of Epidemiological Research, June 23-26, 2010, Seattle, WA.

Beebe-Dimmer J, Schwartz KA, Cetin K, Morgenstern H, Yee C, Bartoces M, Shahinian V, Fryzek J, Acquavella J. Incidence of cataract among elderly prostate cancer patients receiving androgen deprivation therapy in the United States using the Surveillance, Epidemiology, and End Results-Medicare database. Presented at the American Society of Clinical Oncology (ASCO) Annual Conference, June 9-11, 2010, Chicago, IL.

Du Y, Fryzek J, Sekeres MA, Taioli E. 2010. Smoking and alcohol intake as risk factors for myelodysplastic syndromes (MDS). Leuk Res 34(1):1-5.

Beebe-Dimmer JL, Cetin K, Fryzek JP, Schuetze SM, Schwartz K. 2009. The epidemiology of malignant giant cell tumors of bone: An analysis of data from the Surveillance, Epidemiology and End Results Program (1975-2004). Rare Tumors 1(2):e52.

Jensen AØ, Nørgaard M, Yong M, Fryzek JP, Sørensen HT. 2009. Validity of the recorded International Classification of Diseases, 10th edition diagnoses codes of bone metastases and skeletal-related events in breast and prostate cancer patients in the Danish National Registry of Patients. Clin Epidemiol 1:101-108.

Gatto N, Kelsh M, HaMai D, Suh M, Proctor D. A meta-analysis of the relationship between occupational exposure to hexavalent chromium and cancers of the gastrointestinal tract. Society of Toxicology 48th Annual Meeting, Baltimore, MD, March 2009.

Thomsen RW, Thomsen HF, Nørgaard M, Cetin K, McLaughlin JK, Tarone RE, Fryzek JP, Sørensen HT. 2008. Risk of cholecystitis in patients with cancer: A population-based cohort study in Denmark. Cancer 113(12):3410-3419.

Sekeres MA, Schoonen WM, Kantarjian H, List A, Fryzek J, Paquette R, Maciejewski JP. 2008. Characteristics of US patients with myelodysplastic syndromes: Results of six cross-sectional physician surveys. J Natl Cancer Inst 100(21):1542-1551.

Olsen JH, Friis S, Poulsen AH, Fryzek J, Harving H, Tjønneland A, Sørensen HT, Blot W. 2008. Use of NSAIDs, smoking and lung cancer risk. Br J Cancer 98(1):232-237.

Cote ML, Schenk MJ, Schwartz AG, Vigneau FD, Kinnard M, Greenson JK, Fryzek JP, Ying GS, Garabrant DH. 2007. Risk of other cancers in individuals with a family history of pancreas cancer. J Gastrointest Cancer
38(2–4):119–126.

Fryzek JP, Garabrant DH, Schenk M, Kinnard M, Greenson JK, Sarkar FH. The association between selected risk factors for pancreatic cancer and the expression of p53 and K-ras codon 12 mutations. Int J Gastrointest Cancer 37(4):139-145.

Boice JD Jr, Marano DE, Cohen SS, Mumma MT, Blot WJ, Brill AB, Fryzek JP, Henderson BE, McLaughlin JK. 2006. Mortality among Rocketdyne workers who tested rocket engines, 1948-1999. J Occup Environ Med 48(10):1070-1092.

Fryzek JP, Poulsen AH, Lipworth L, Pedersen L, Nørgaard M, McLaughlin JK, Friis S. 2006. A cohort study of antihypertensive medication use and breast cancer among Danish women. Breast Cancer Res Treat 97(3):231-236.

Fryzek JP, Schenk M, Kinnard M, Greenson JK, Garabrant DH. 2005. The association of body mass index and pancreatic cancer in residents of southeastern Michigan, 1996-1999. Am J Epidemiol 162(3):222-228.

Fryzek JP, Chadda B, Marano D, White K, Schweitzer S, McLaughlin JK, Blot WJ. 2003. A cohort mortality study among titanium dioxide manufacturing workers in the United States. J Occup Environ Med 45(4):400-409.

Boice JD Jr, Mumma M, Schweitzer S, Blot WJ. 2003. Cancer mortality in a Texas county with prior mining and milling activities, 1950–2001. J Radiol Prot 23:247–262.

Fryzek JP, Ye W, Signorello LB, Lipworth L, Blot WJ, McLaughlin JK, Nyren O. 2002. Incidence of cancer among patients with knee implants in Sweden, 1980-1994.Cancer 94(11):3057-3062.

Signorello LB, Ye W, Fryzek JP, Lipworth L, Fraumeni JF Jr, Blot WJ, McLaughlin JK, Nyrén O. 2001. Nationwide study of cancer risk among hip replacement patients in Sweden. J Natl Cancer Inst 93(18):1405-1410.

Fryzek JP, Mumma MT, McLaughlin JK, Henderson BE, Blot WJ. 2001. Cancer mortality in relation to environmental chromium exposure. J Occup Environ Med 43(7):635-640.

Fryzek JP, Mellemkjaer L, McLaughlin JK, Blot WJ, Olsen JH. 1999. Cancer risk among patients with finger and hand joint and temporo-mandibular joint prostheses in Denmark. Int J Cancer 81(5):723-725.